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cense. httpAbstract Background: Endometrial cancer is the most prevalent cancer of the female genital tract
in North America. Minimally invasive laparoscopic-assisted surgery and panniculectomy in obese
women with endometrial cancer are associated with an improved lymph node count, and lower rate
of incisional complications than laparotomy.
Methods: Technique for robot-assisted laparoscopic surgery for obese women with endometrial
cancer is detailed.
Results: Robot-assisted laparoscopic surgical staging, pelvic and para-aortic lymphadenectomy
and panniculectomy allow us to avoid the use of postoperative pelvic radiation which is recom-
mended in women with histopathology high-risk ﬁndings: deep myometrial invasion or high grade
histology. The procedure has the advantage of three-dimensional vision, ergonomic, intuitive con-
trol, and wristed instrument that approximate the motion of the human hand.
Conclusion: Robot-assisted laparoscopic surgical staging, and panniculectomy in these patients are
a safe, and effective alternative to laparoscopic, and laparotomy surgery. It is an ideal tool for per-
forming the complex oncologic procedures encountered in endometrial cancer staging that requires
delicate retroperitoneal, pelvic and para-aortic lymph node dissection, while maintaining the prin-
ciples of oncologic surgery but in a minimally invasive fashion.
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Uterine cancer is the most common gynecological cancer in the
USA. The American Cancer Society estimates about 47,130
new cases of cancer of the body of the uterus, and about
8010 deaths in 2012. These numbers include both endometrial
cancers and uterine sarcomas. About 2% of uterine body can-
cers are sarcomas. The median age of diagnosis of endometrial
cancer is 63 years, and the median age of death is 73 years. Inational Cancer Institute, Cairo University.
.002
58 S.A. Farghalythe US, the highest incidence is in Caucasian women, with 24.3
per 100,000 per year, and the highest mortality is in African–
American women with 7.6 per 100,000 per year. The majority
of these cases are endometrial cancers. The operative manage-
ment of these cases is hysterectomy with bilateral salpingo-
oophorectomy. The American College of Obstetricians and
Gynecologists recommends lymphadenectomy for all patients
except in young women with low grade tumor in a background
of complex endometrial hyperplasia or women with signiﬁcant
co morbidities [1]. It has been shown that 77% of patients with
para-aortic node involvement had metastasis above the infe-
rior mesenteric artery. Pelvic and para-aortic lymphadenec-
tomy up to the renal vessels is indicated in those patients.
The latter should include excision of the gonadal veins. Con-
versely, lymphadenectomy does not beneﬁt patients with grade
1 or 2 endometrioid lesions with myometrial invasion less or
equal to 50% or primary tumor diameter less than or equal
to 2 cm [2]. Risk factors for the development of endometrial
cancer include early menarche, late menopause, history of
infertility, anovularity cycles, nulliparity, obesity, tamoxifen
use, hereditary nonpolyposis colorectal cancer (NHPCC or
Lynch syndrome), estrogen-secreting tumors (i.e., granulose
cell), estrogen therapy, diabetes, and prior pelvic radiation
[3]. Approximately 85% of endometrial cancers are of endome-
trioid histology. The remaining 15% are of papillary serous
and clear cell cancers. Type I uterine cancer is considered to
be grade 1 and 2 endometrioid adenocarcinoma. It is common
in peri-and post menopausal obese women and in women tak-
ing unopposed estrogen. Type II is composed of grade 2 endo-
metrioid adenocarcinomas, papillary serous and clear cell
cancers. These cancers are more aggressive with tendency to
present with advanced-stage disease.
Laparoscopic assisted surgery for endometrial cancer
The re-emergence of radical vaginal surgery and the ability to
perform complete laparoscopic staging procedures have al-
lowed minimally invasive surgery to have a very important role
in patients with gynecological cancer. It has been shown that,
minimally invasive surgery in the management of early-stage
endometrial cancer is safe, and feasible. It lowers hospital costs
and produce results comparable with those of abdominal ap-
proach. The laparoscopic procedure includes laparoscopically
assisted or total vaginal hysterectomy with pelvic and para-
aortic lymph node dissection, peritoneal washings, and an
omentectomy in patients with serous type malignancies of
the endometrium. Abu-rustum et al. [4] have described these
procedures in the management of endometrial carcinoma.
The laparoscopic surgery for endometrial cancer has been
compared with open laparotomy surgery. There was no differ-
ence between the two groups with regard to mean Quetelet in-
dex, number of lymph nodes and mean operating time. The
recurrence-free survival rate was not signiﬁcantly different be-
tween the laparoscopy (97.3%) and laparotomy (93.3%)
groups. The survival rate was 83.9% in the laparoscopic group
and 90.9% in the laparotomy group. Thorough pelvic and par
aortic lypmhadenectomy is important, as the extent of lym-
phadenectomy is related to the number of metastatic lymph
nodes identiﬁed. Patients undergoing multiple-site lymphade-
nectomy have a signiﬁcantly better survival than did those pa-
tients not undergoing lymphadenectomy. Low-risk patients
(disease conﬁned to the uterus) with lymphadenectomy havebetter survival than those without lymphadenectomy. High
risk patients (disease in the cervix, adenexae, uterine serosa,
or washings) who undergo lymphadenectomy also have a bet-
ter survival than did those without lymphadenectomy. In addi-
tion, it seems feasible that partial vaginectomy of the upper
one third of the vagina would minimize the chances of vaginal
vault recurrence [5].
Port site tumor implantation following laparoscopic surgery
While laparoscopic procedures for gynecologic cancer continue
to be effective with favorable outcomes conﬁrmed, reports of
metastases at the site of trocar insertion (PSMs) have been re-
ported. Ramirez et al. [6] estimated that the overall incidence
of PSMs after laparoscopic surgery for gynecologic cancer was
1–2%.There are several postulated causes for developing PSMs;
of these, tumor aggressiveness appears to be the most favored.
From theCancer biology standpoint, themore aggressive the tu-
mor, the most likely that tumor is to metastasize. In an experi-
mental study on rats using intraluminal tracer, Polate et al. [7]
showed that trocar-site contamination was more common when
the primary tumor manipulated traumatically. Hence, it pro-
motes the tumor cell seeding. Immune depressionmight be a fac-
tor predisposing to metastases, including the port sites. It is well
recognized that the trauma of surgery can depress immune func-
tion and this in theory predispose to the spread of tumor metas-
tases. Animal models have shown that the body immune system
is signiﬁcantly more depressed after open surgery than after lap-
aroscopy, and this might explain why PSMs appear less com-
monly than wound metastases from open surgery [8]. It has
been recommended that peritoneal lavage with large volumes
of saline and 500 U/L heparin would decrease the adherence
of malignant cells to a denuded surface [9]. Jurczok et al. [10]
showed that in a murine model, tumor implantation and PSMs
after laparoscopic surgerymight be prevented by intraperitoneal
administration of speciﬁc oligopeptides or cytotoxic agents such
as mitomycin. It is reasonable to assume that if the following
protective measures are applied, it will, undoubtedly, decrease
the risk of the development of port-site metastasis: trocar ﬁxa-
tion, prevention of insufﬂation gas leaks, rinsing of instruments
with 1% povidine–iodine solution, minilaparotomy protection,
rinsing off trocars with 1% povidine–iodine solution [11].Surgical approach to obese women
The incidence of obesity among American women has in-
creased dramatically over the past 40 years. Obese women
undergoing pelvic surgery are more likely to experience intra-
operative and postoperative complications. Pitkin [12] re-
ported the effect of overweight in patients undergoing
gynecological surgery. Those patients had longer operating
times, increased blood loss, postoperative wound complica-
tions, and febrile morbidity. Similarly, obese women undergo-
ing surgery for endometrial cancer have longer operating
times, greater blood loss, longer hospital stays, higher rate of
wound infection, and wound dehiscence [13]. Obesity is associ-
ated with a 10-fold increased risk for endometrial cancer. Ob-
ese patients have an increased risk of laparotomy conversion
and less complete lymph nodal dissection [14]. Maintenance
of exposure during aortic lymph node dissection and adequate
ventilation can be a challenge to the gynecological surgeon and
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ing and standardization of surgical approaches that allow ade-
quate staging is important. Laparoscopic surgery for
endometrial cancer, in obese women, is impeded by thick adi-
pose tissue interfering with trocar placement, less adequate
peritoneal distension, intraperitoneal adipose tissue hindrance,
lymph node dissection, and a bulky omental and mesenteric fat
obstructing adequate retraction of the bowel and omentum
during lymph node dissection. It has been shown that women
with body mass index (BMI) of more than 40 were more likely
to have tumor and a lower stage than women with BMI of less
than 30 [15]. Also, it has been suggested that obesity was asso-
ciated with favorable pathological variables and trend toward
increased survival. In addition, obese women develop endome-
trial cancer through the hormone-dependent pathway (type I
endometrial cancer) relative to normal weight patients who
may develop the disease through autonomous oncogenesis
(type II). Obese patients are noted to more likely have lower
grade histology when compared to normal weight patients.
Conversely, normal weight patients with endometrial cancer
had signiﬁcantly higher rates of high-grade histology and were
signiﬁcantly of younger age group. Obese women less fre-
quently have the DNA mismatch repair gene mutations that
result in hereditary nonpolyposis colorectal carcinoma
(HNPCC) and therefore fewer metachronons HNPCC-related
cancer. For patients undergoing surgery for endometrial can-
cer, it is important to evaluate obesity by measuring body mass
index, waist-to-hip ratio, waste circumference, and intra-
abdominal visceral fat (IVF) assessment using ultra sonogra-
phy and computed tomography. Intra-abdominal visceral fat
computed tomography is a reliable predictor to choose the
type of surgery either the laparoscopic or laparotomy ap-
proach [16]. It is, generally accepted that panniculectomy im-
proved operative exposure, staging, and increased pelvic and
paraaortic lymph node yield and well tolerated in patients
undergoing surgery for endometrial cancer [17]. Abdominal
panniculectomy is performed for several reasons a large pan-
nus can cause chronic irritation, rashes, chronic ulcers and ﬁs-
tulas and could decrease the pulmonary reserve. Wound and
post-operative complications are directly proportional to the
degree of obesity [18]. Risks associated with operating through
a large pannus include limited surgical exposure, increased
blood loss, increased operative time, increased thromboembo-
lic complications and decreased wound healing [19].
It seems feasible to assume that robotic assisted panniculec-
tomy using the da Vinci system in patients with endometrial
cancer is practical and safe. Care must be taken when raising
the superior adipocutaneous ﬂap to only dissect enough to
provide adequate exposure for the procedure and to allow clo-
sure with minimal tension on the skin edges. The umbilicus
should be preserved to minimize wound problems. The umbi-
licus could be excised in case of umbilical hernia, an umbilical
stalk that is longer than 5 cm, or a previous open cholecystec-
tomy. Also, the umbilicus could be scariﬁed, if the abdominal
wall thickness is such that excessive tension would be put on
the stalk to exteriorize the umbilicus. To minimize wound
complications, the deep muscle fascia should be incorporated.
Some of the sutures are used for Scarpa fascia closure to min-
imize the dead space. The dermis and the superﬁcial fat are
closed with a separate layer of sutures, and then surgical sta-
ples applied to skin. Every staple is removed after 6 days.Adequate wound drainage with drains should prevent the
formation of serous seromas which may later become infected.
Role of robot-assisted laparoscopic surgery in endometrial
cancer
Surgeons’ experience, training and limitations of oncologic
laparoscopic surgery that include counter-intuitive emotion,
non-wristed instrumentation and a reliance of skilled surgical
assistance contribute to a difﬁcult and long learning curve.
Laparoscopic surgery for endometrial cancer is more difﬁcult
in patients with adhesive disease, large uteri, fatty mesentery,
and inability to tolerate steep Trendelenberg. Robotic-assisted
surgery leverages the advantages of standard laparoscopy
while restoring three-dimensional vision, ergonomic, intuitive
controls, and wristed instruments that approximate the motion
of the human hand. The only absolute contraindications to ro-
botic surgery are:
(1) Patients who cannot tolerate general anesthesia,
(2) Patients who cannot tolerate a steep Trendelenberg
position.
For many institutions, assisted robotic surgery has become
the technique of choice for performing surgical staging includ-
ing hysterectomy, and lymphadenectomy for endometrial can-
cer patients. Robotic assisted surgical staging is feasible in
obese patients with endometrial cancer and may result in com-
parable outcomes as patients are staged by laparotomy with
fewer complications and shorter length of hospital stay. It
has been shown that 15.6% (95% conﬁdence interval {CI}
9.5–24.25%) of obese patients who underwent robotic-assisted
surgery for endometrial cancer were converted to laparotomy
[20]. The advantage of using this method was satisfactory
lymph node yield, low blood loss; reasonable operative time
with short hospital stays [21]. Farghaly’s technique of robot -
assisted laparoscopy for treatment of obese patients with endo-
metrial cancer utilizes the da Vinci surgical system, and in-
volves perioperative mechanical bowel prep with 4 L of
polyethylene glycol [Golytely (R)]. The day prior to surgery
a pressure-controlled anesthesia is used for ventilating patients
in steep Trendlenberg. After induction of anesthesia, the pa-
tient is placed in the low dorsolithotomy position using univer-
sal Allen stirrups. A gel pad is placed underneath the patient
on the surgical table. The patient’s arms are tucked to her
sides, and shoulder block is placed to minimize patient’s posi-
tion shifts and prevent nerve injury. Then a large rectal dilator
(EEA sizer) is placed in the vagina with a pneumo-occluder
balloon). The patient is prepped and draped in a standard
fashion. A ﬁve-trocar transperitoneal approach is used. A
2 mm laparoscopic port is placed in the left upper quadrant
2 cm below the costal margin in the mid clavicular line. All
subsequent ports are placed under direct visualization. The
abdomen, is then, insufﬂated with CO2 gas to a maximum
pressure of 15 mmHg. The patient is subsequently placed in
a steep Trendelenburg position, and the secondary trocars
are placed. After that, the 2 mm left upper quadrant port is
converted to a 10–12 mm assistants’ port. The da Vinci (R)
surgical system is then docked between the legs at the foot of
the bed. A zero-degree camera is used for the entire procedure.
Maryland grasper is used in the left robotic arm; also a bipolar
60 S.A. Farghalyendo wrist instrument is placed in the fourth robotic arm and
used for retraction. The surgical procedure begins with right
robotic lymphadenectomy, followed by left aortic dissection,
pelvic lymphadenectomy and total hysterectomy. The bound-
aries of dissection of the pelvic-aortic lymphadenectomy are
consistent with the Gynecologic Oncology Group (GOG) sur-
gical procedures manual [22]. For pelvic lymphadenectomy,
this includes the middle psoas muscle (laterally), deep circum-
ﬂex iliac vein (inferiorly), mid-common iliac vessels (superi-
orly), and obturator nerve (posteriorly). The aortic lymph
node dissection superior boundaries are to the ovarian vessel
on the right and to the inferior mesenteric artery on the left.
Monopolar spatula instrument is used in the right hand and
a plasma kinetic grasper in the left hand. For large pedicles
an Ensel Tissue sealing system (Surg Rx, Redwood, California,
USA) or Ligasure tissue Fusion System (Valley Lab, Boulder,
Colorado, USA) was used for a combined vessel sealing and
cutting through the assistant’s port. A vaginotomy is per-
formed. The specimens are placed in endocatch (R) bags and
delivered vaginally. The vaginal cuff is closed with two 0-vicryl
sutures on a CT-1 needle cut to 12 in., starting from each cor-
ner and meeting in the middle. Postoperatively, the patient is
given a regular diet the night of surgery and oxycodone/acet-
aminophen for pain relief. The Foley catheter is left in place
and discharged from the hospital and a voiding trial is sched-
uled in the clinic within 1 week. The patient is discharged on
post operative day 2. Seamon et al. [23] reported that, of 105
patients with endometrial cancer, 13 (12.4%) with a BMI rang-
ing from 47 to 58 and grade 1 cancer did not undergo complete
staging: six patients underwent pelvic lymphadenectomy with-
out aortic dissection and seven had no lymphatic staging.
There were also 12.4% conversions to laparotomy. The mean
conversion BMI was 40 ± 7 kg/m2 compared to 34 ± 9 kg/m2
for those completed robotically. The feasibility for completing
robotic aortic lymphadenectomy was 67% and 35% for BMI
45 and 50 kg/m2, respectively. Subramaniam et al. [24] com-
pared outcomes for a group of obese patients with endometrial
cancer undergoing robotic and open hysterectomy. Lymphad-
enectomy (total mean node count 8.0) was performed in 66%
of robotic cases and conversion to laparotomy was 11%.
Blood transfusions, hospital stay and complications were all
improved in the robotic-assisted surgery group.
Surgical cost comparison
In the model of Barnett et al. [25], laparoscopy was least
expensive at $10128.00 per case. Robotic surgery and open sur-
gery costs exceeded laparoscopy by $1348 and $2719, respec-
tively. The authors proposed that reducing disposable costs
for the robot to $1046 from the average reported at $2394
would make it equal to laparoscopy. This analysis makes sev-
eral assumptions about institution-speciﬁc variables that could
inﬂuence the amortized per-case costs of the da Vinci system
and laparoscopic equipment. High volume centers can reduce
the cost gap between robotics and laparoscopy because the
per-case cost of the da Vinci system is reduced. Jonsdottir
et al. [26] hypothesized that, robotic surgeons and their operat-
ing room teams improved efﬁciencies with reductions in oper-
ative and turnover times. The study showed the importance of
analyzing costs over time for institutions, as efﬁciencies may be
gained or lost as the patterns of care change.Conclusion
Robot-assisted laparoscopic panniculectomy combined with
radical hysterectomy and pelvic and para aortic lymphadenec-
tomy in obese patient with endometrial cancer is a safe and
effective alternative to laparoscopic and laparotomy surgery.
It has the advantage of three-dimensional vision, ergonomic,
intuitive control, and wristled instrument that approximate
the motion of the human hand. It can decrease the incidence
of intraoperative complications and post operative wound
complications without signiﬁcantly increasing operative time
or blood loss. The procedure is cost effective with acceptable
operative, pathological and short and long term clinical out-
come. It retains the advantage of minimally invasive surgery.Conﬂict of interest
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